MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
17.07
-0.12
-0.70%
After Hours: 16.50 -0.57 -3.34% 16:30 04/18 EDT
OPEN
17.26
PREV CLOSE
17.19
HIGH
17.35
LOW
17.01
VOLUME
988.32K
TURNOVER
0
52 WEEK HIGH
33.99
52 WEEK LOW
16.60
MARKET CAP
2.81B
P/E (TTM)
-45.6295
1D
5D
1M
3M
1Y
5Y
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting. The presentations include outcomes from the DAFFODIL™ study evaluating the safety, tolerability and exploratory efficacy of daybUE in girls aged two to four living with rett syndrome. Rett Syndrome is a rare, complex neurodevelopmental disorder.
Barchart · 1d ago
Weekly Report: what happened at ACAD last week (0408-0412)?
Weekly Report · 3d ago
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
ACADIA Pharmaceuticals has an average price target of $33.2. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes drugs for central nervous system disorders. 26 analysts have expressed a variety of opinions on ACADIA pharmaceuticals over the past quarter. The 12-month price targets assessed by analysts show an average of $19.00 for the company.
Benzinga · 04/10 20:01
ACADIA Pharmaceuticals Price Target Maintained With a $37.00/Share by Cantor Fitzgerald
Dow Jones · 04/10 13:44
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
Benzinga · 04/10 13:33
ACADIA PHARMACEUTICALS INC <ACAD.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $28 FROM $33
Reuters · 04/10 03:27
Taysha draws bullish view at Piper Sandler on lead asset
Taysha Gene Therapies' lead asset, TSHA-102, targeted at the rare neurodevelopmental disorder Rett syndrome. Piper Sandler has an Overweight recommendation on the stock and a $9 price target. The company's lead asset represents a more than $900M revenue opportunity.
Seeking Alpha · 04/09 19:16
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/09 10:40
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.